Clinical trial
Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable…
NCT00072345 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00072345 |
|---|---|
| Title | Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma |
| Official title | A Phase II Study of Temozolomide, Thalidomide, and Lomustine in the Treatment of Advanced Melanoma |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Intraocular Melanoma, Melanoma (Skin) |
| Intervention type | Drug |
| Interventions | lomustine, temozolomide, thalidomide |
| Start date | Jul 1, 2003 |
| Primary completion | Aug 1, 2004 |
| First posted | Nov 6, 2003 |
| Last update posted | Jan 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: